Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT

Summary

The objective of this study was to explore whether the combination with umbilical cord blood (UCB) is associated with superior disease-free survival (DFS) in the setting of haploidentical donors (HID) transplantation.

Conditions

• Hematological Malignancies
• Hematopoietic Stem Cell Transplantation

Interventions

OTHER

PBSCs

PBSCs harvest is performed from day 5 of G-CSF to obtain at least 7.0×10\^8 total nucleated cells/kg recipient ideal body weight.

OTHER

Cord

The criteria for cord selection included the following: (1) ≥3 of 6 HLA loci , (2) blood type matches, (3) contained a minimum cell count of 0.3×10\^8 nucleated cells/kg and 0.15×10\^6 CD34-positive cells/kg before freezing. The third party UCB will be infused the day after infusion of PBSCs.

OTHER

BMSCs

BMSCs of donor will be collected and infused at least 0.5×10\^8 total nucleated cells/kg recipient ideal body weight the day after PBSCs infusion.

Sponsors & Collaborators

• First Affiliated Hospital of Guangxi Medical University

  collaborator OTHER

• Hunan Provincial People's Hospital

  collaborator OTHER

• The Seventh Affiliated Hospital of Sun Yat-sen University

  collaborator OTHER

• First People's Hospital of Chenzhou

  collaborator OTHER

• Dongguan People's Hospital

  collaborator OTHER_GOV

• The First People's Hospital of Guangzhou

  collaborator UNKNOWN

• Nanfang Hospital, Southern Medical University

  lead OTHER

Principal Investigators

• Qifa Liu · Nanfang Hospital, Southern Medical University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-02-15

Primary Completion

2023-01-02

Completion

2024-03-30

Countries

• China

Study Locations